Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by ScienceFirston May 26, 2022 8:35pm
145 Views
Post# 34710816

RE:RE:#ASCO22 Annual Meeting - June 3-7, 2022

RE:RE:#ASCO22 Annual Meeting - June 3-7, 2022So funny.

In their 2018 animal models (mice), they only obtained tumor regressions in mice.  Not even tumor destructions! 

And they have to discriminate among patients (anti-PD-1), so their pool of patients is much narrower (3-4x, or about only 25% of the elegible patients) than would be our PDT/PDC technology.



Abstract 2790: The anti-TGFβ neutralizing antibody, SAR439459, blocks the immunosuppressive effects of TGFβ and inhibits the growth of syngeneic tumors in combination with anti-PD1


However, the combination of anti-PD-1 and SAR439459 led to tumor regression in the majority of tumor-bearing mice.

These results provide the rationale for combining TGF-β neutralization with checkpoint inhibitors, specifically anti-PD1, for the treatment of human cancers.



_________________________________

ScienceFirst - (5/26/2022 8:04:46 PM)

RE:#ASCO22 Annual Meeting - June 3-7, 2022

Another big pharma that we could compare against their innovative oncology pipeline, to see where we stand and what they mean about "innovation":


May 17, 2022:


SANOFI Media Update: New data from fast-growing innovative Oncology pipeline and portfolio to be presented at 2022 ASCO Annual Meeting

Safety and efficacy data for SAR439459, a transforming growth factor beta (TGF-β) inhibitor*

Abstract 2524: Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFβ inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors

<< Previous
Bullboard Posts
Next >>